Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | AGT | P01019 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924610 | 0.93 | AGTR2 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6024537 | 0.92 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL8792233 | 0.89 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL641 | 0.89 | AGTR1 (0.56) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL14855493 | 0.89 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL498022 | 0.88 | AGTR2 (0.63) | AGTR1AGTR2AGT | |
| SCHEMBL9314520 | 0.88 | AGTR1 (0.57) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6711100 | 0.88 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL9313215 | 0.87 | AGTR2 (0.56) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL1257668 | 0.87 | AGTR2 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287537-A1 | Method of removing the triphenylmethane protecting group | ZENTIVA, A.S. (CZ) | 2006-12-21 | — | — | US | claimed |
| EP-1658281-A2 | A METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTING GROUP | Zentiva, a.s. (CZ) | 2006-05-24 | — | — | EP | claimed |
| WO-2005021535-A2 | A METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTING GROUP | ZENTIVA, A.S. (CZ) | 2005-03-10 | — | — | WO | claimed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-9012485-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8895755-B2 | Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140303222-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8664254-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-4874867-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4870186-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| US-4820843-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287537-A1 | Method of removing the triphenylmethane protecting group | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885ABCC4 3624/4885 |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885ABCC4 2211/4885 |
| US-20140303222-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885ABCC4 2211/4885 |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885ABCC4 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.